Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children

BMC Infectious Diseases

Volumn 6, Issue , 2006, Pages

  Resino, Salvador ^a   Larrú, Beatriz ^b   Bellón, Jose Ma ^a   Resino, Rosa ^a   de José, Ma Isabel ^b   Navarro, Marisa ^a   Léon, Juan Antonio ^c   Ramos, José Tomás ^d   Mellado, Ma José ^b   Muñoz Fernández, Ma Ángeles ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; CHOLESTEROL; DIDANOSINE; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADOLESCENT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; INFANT; LIVER TOXICITY; LOGISTIC REGRESSION ANALYSIS; LONG TERM CARE; MALE; MULTICENTER STUDY; NONHUMAN; PATIENT MONITORING; PHYSICAL EXAMINATION; PREDICTION; REFERENCE VALUE; SIDE EFFECT; VERTICAL TRANSMISSION; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; NELFINAVIR; PROSPECTIVE STUDIES; VIRAL LOAD;

EID: 33747199314     PISSN: 14712334     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-6-107     Document Type: Article

References (18)

1. de Martino M, Tovo PA, Balducci M, Galli L, Gabiano C, Rezza G, Pezzotti P: Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry. JAMA 2000, 284:190-197.
2. Resino S, Bellón JM, Resino R, Navarro ML, Ramos JT, Mellado MJ, de Jose MI, Muñoz-Fernández MA: Extensive implementation of highly active antiretroviral therapy shows great effectiveness on the survival and surrogate markers in vertically HIV-infected children. Clin Infect Dis 2004, 38:1605-1612.
3. Krogstad P, Lee S, Johnson G, Stanley K, McNamara J, Moye J, Jackson JB, Aguayo R, Dieudonne A, Khoury M, Mendez H, Nachman S, Wiznia A: Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1. Clin Infect Dis 2002, 34:991-1001.
4. Nadal D, Steiner F, Cheseaux JJ, Lazarevitch CA, Aebi C, Kind C, Rudin C: Long-term responses to treatment including ritonavir or nelfinavir in HIV-I-infected children. Pediatric AIDS Group of Switzerland. Infection 2000, 28:287-296.
5. Gatti G, Castelli-Gattinara G, Cruciani M, Bernardi S, De Pascalis CR, Pontali E, Papa L, Miletich F, Bassetti D: Pharmacokinetics and pharmacodynamics of nelfinavir administered twice or thrice daily to human immunodeficiency virus type 1-infected children. Clin Infect Dis 2003, 36:1476-1482.
6. Litalien C, Faye A, Compagnucci A, Giaquinto C, Harper L, Gibb DM, Jacqz-Aigrain E: Pharmacokinetics of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1. Pediatr Infect Dis J 2003, 22:48-55.
7. Starr SE, Fletcher CV, Spector SA, Yong FH, Fenton T, Brundage RC, Manion D, Ruiz N, Gersten M, Becker M, McNamara J, Mofenson LM, Purdue L, Siminski S, Graham B, Kornhauser DM, Fiske W, Vincent C, Lischner HW, Dankner WM, Flynn PM: Combination therapy with efavirenz, nelfinavir, and nucleoside reverse- transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. N Engl J Med 1999, 341:1874-1881.
8. Resino S, Bellón JM, Ramos JT, Gonzalez-Rivera M, de José MI, González MI, Gurbindo D, Mellado MJ, Cabrero E, Muñoz-Fernández MA: Positive virologic outcome after lopinavir/ritonavir salvage therapy in protease inhibitor-experienced HIV-1-infected children. A prospective cohort study. J Antimicrob Chemother 2004, 54:921-931.
9. Murphy RL, Brun S, Hicks C, Eron JJ, Gulick R, King M, White ACJ, Benson C, Thompson M, Kessler HA, Hammer S, Bertz R, Hsu A, Japour A, Sun E: ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS 2001, 15:F1-9.
10. Hurst M, Faulds D: Lopinavir. Drugs 2000, 60:1371-1381.
11. Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, Johnson M, Johnson D, Lalonde R, Japour A, Brun S, Sun E: Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002, 346:2039-2046.
12. Saez-Llorens X, Violari A, Deetz CO, Rode RA, Gomez P, Handelsman E, Pelton S, Ramilo O, Cahn P, Chadwick E, Allen U, Arpadi S, Castrejon MM, Heuser RS, Kempf DJ, Bertz RJ, Hsu AF, Bernstein B, Renz CL, Sun E: Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2003, 22:216-224.
13. Lee GA, Mafong DD, Noor MA, Lo JC, Mulligan K, Schwarz JM, Schambelan M, Grunfeld C: HIV protease inhibitors increase adiponectin levels in HIV-negative men. J Acquir Immune Defic Syndr 2004, 36:645-647.
14. Lee GA, Seneviratne T, Noor MA, Lo JC, Schwarz JM, Aweeka FT, Mulligan K, Schambelan M, Grunfeld C: The metabolic effects of lopinavir/ ritonavir in HIV-negative men. Aids 2004, 18:641-649.
15. Machado ES, Lambert JS, Afonso AO, Cunha SM, Oliveira RH, Tanuri A, Sill AM, Costa AJ, Soares MA: Alternative, age- and viral load-related routes of nelfinavir resistance in human immunodeficiency virus type 1-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J 2004, 23:1057-1059.
16. Saitoh A, Singh KK, Powell CA, Fenton T, Fletcher CV, Brundage R, Starr S, Spector SA: An MDRI-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. Aids 2005, 19:371-380.
17. Resino S, Gurbindo MD, Bellón JM, Sanchez-Ramón S, Muñoz-Fernández MA: Predictive markers of clinical outcome in vertically HIV-1 infected infants. A prospective longitudinal study. Pediatr Res 2000, 47:509-515.
18. Storm DS, Boland MG, Gortmaker SL, He Y, Skurnick J, Howland L, Oleske JM: Protease inhibitor combination therapy, severity of illness, and quality of life among children with perinatally acquired HIV-1 infection. Pediatrics 2005, 115:e173-82.